Home - News ( United States | United Kingdom | Italy | Germany ) - Football scores

Showing content from https://link.springer.com/doi/10.1007/BF01221030 below:

The chemosensitizer cyclosporin A enhances the toxic side-effects of doxorubicin in the rat

• Bissett D, Kerr DJ, Cassidy J, Meredith P, Traugott U, Kaye SB (1991) Phase I and pharmacokinetic study ofd-verapamil and doxorubicin. Br J Cancer 64:1168–1171

  Google Scholar 

• Boesch D, Gavériaux C, Jachez B, Pourtier-Manzanedo A, Bollinger P, Loor F (1991) In vivo circumvention of P-glycoprotein-mediated multidrug resistance of tumor cells with SDZ PSC 833. Cancer Res 51:4226–4233

  Google Scholar 

• Bright JM, Buss DD (1990) Effects of verapamil on chronic doxorubicin-induced cardiotoxicity in dogs. J Natl Cancer Inst 82:963–964

  Google Scholar 

• Bristow MR, Lopez MB, Mason JW, Billingham ME, Winchester MA (1982) Efficacy and cost of cardiac monitoring in patients receiving doxorubicin. Cancer 50:32–41

  Google Scholar 

• Chin K-V, Pastan I, Gottesman MM (1993) Function and regulation of the human multidrug resistance gene. Adv Cancer Res 60:157–180

  Google Scholar 

• Dalton WS, Grogan TM, Meltzer PS, Scheper RJ, Durie BGM, Taylor CW, Miller TP, Salmon SE (1989) Drug-resistance in multiple myeloma and non-Hodgkin's lymphoma: detection of P-glycoprotein and potential circumvention by addition of verapamil to chemotherapy. J Clin Oncol 7:415–424

  Google Scholar 

• Figueredo A, Arnold A, Goodyear M, Findlay B, Neville A, Normandeau R, Jones A (1990) Addition of verapamil and tamoxifen to the initial chemotherapy of small cell lung cancer. A phase I/II study. Cancer 65:1895–1902

  Google Scholar 

• Fojo AT, Ueda K, Slamon DJ, Poplack DG, Gottesman MM, Pastan I (1987) Expression of a multidrug-resistance gene in human tumors and tissues. Proc Natl Acad Sci USA 84:265–269

  Google Scholar 

• Ford JM, Hait WN (1990) Pharmacology of drugs that alter multidrug resistance in cancer. Pharmacol Rev 42:155–199

  Google Scholar 

• Genne P, Coudert B, Pelletier H, Girardot C, Martin F, Chauffert B (1989) Serum concentrations of amiodarone required for an in vivo modulation of anthracycline resistance. Anticancer Res 9:1655–1660

  Google Scholar 

• Goldstein LJ, Galski H, Fojo A, Willingham M, Lai S-L, Gazdar A, Pirker R, Green A, Crist W, Brodeur GM, Lieber M, Cossman J, Gottesman MM, Pastan I (1989) Expression of a multidrug resistance gene in human cancers. J Natl Cancer Inst 81:116–124

  Google Scholar 

• Herweijer H, Sonneveld P, Baas F, Nooter K (1990) Expression of mdr1 and mdr3 multidrug-resistance genes in human acute and chronic leukemias and association with stimulation of drug accumulation by cyclosporine. J Natl Cancer Inst 82:1133–1140

  Google Scholar 

• Horton JK, Thimmaiah KN, Houghton JA, Horowitz ME, Houghton PJ (1989) Modulation by verapamil of vincristine pharmacokinetics and toxicity in mice bearing human tumor xenografts. Biochem Pharmacol 38:1727–1736

  Google Scholar 

• Lenaz L, Page JA (1976) Cardiotoxicity of Adriamycin and related anthracyclines. Cancer Treat Rev 3:111–120

  Google Scholar 

• List AF, Spier C, Greer J, Wolff S, Hutter J, Dorr R, Salmon S, Futscher B, Baier M, Dalton W (1993) Phase I/II trial of cyclosporine as a chemotherapy-resistance modifier in acute leukemia. J Clin Oncol 11:1652–1660

  Google Scholar 

• Lum BL, Kaubisch S, Yahanda AM, Adler KM, Jew L, Ehsan MN, Brophy NA, Halsey J, Gosland MP, Sikic BI (1992) Alteration of etoposide pharmacokinetics and pharmacodynamics by cyclosporine in a phase I trial to modulate multidrug resistance. J Clin Oncol 10:1635–1642

  Google Scholar 

• Mettler FP, Young DM, Ward JM (1977) Adriamycin-induced cardiotoxicity (cardiomyopathy and congestive heart failure) in rats. Cancer Res 37:2705–2713

  Google Scholar 

• Mickisch GH, Licht T, Merlino GT, Gottesman MM, Pastan I (1991) Chemotherapy and chemosensitization of transgenic mice which express the human multidrug resistance gene in bone marrow: efficacy, potency, and toxicity. Cancer Res 51:5417–5424

  Google Scholar 

• Miller RL, Bukowski RM, Budd GT, Purvis J, Weick JK, Shepard K, Midha KK, Ganapathi R (1988) Clinical modulation of doxorubicin resistance by the calmodulin-inhibitor, trifluoperazine: a phase I/II trial. J Clin Oncol 6:880–888

  Google Scholar 

• Osieka R, Seeber S, Pannenbäcker R, Soll D, Glatte P, Schmidt CG (1986) Enhancement of etoposide-induced cytotoxicity by cyclosporin A. Cancer Chemother Pharmacol 18:198–202

  Google Scholar 

• Philip PA, Joel S, Monkman SC, Dolega-Ossowski E, Tonkin K, Carmichael J, Idle JR, Harris AL (1992) A phase I study on the reversal of multidrug resistance (MDR) in vivo: nifedipine plus etoposide. Br J Cancer 65:267–270

  Google Scholar 

• Philips FS, Gilladoga A, Marquardt H, Sternberg SS, Vidal PM (1975) Some observations on the toxicity of Adriamycin (NSC-123127). Cancer Chemother Rep 6:177–181

  Google Scholar 

• Slater LM, Sweet P, Stupecky M, Wetzel MW, Gupta S (1986) Cyclosporin A corrects daunorubicin resistance in Ehrlich ascites carcinoma. Br J Cancer 54:235–238

  Google Scholar 

• Solary E, Caillot D, Chauffert B, Casasnovas R-O, Dumas M, Maynadie M, Guy H (1992) Feasibility of using quinine, a potential multidrug resistance-reversing agent, in combination with mitoxantrone and cytarabine for the treatment of acute leukemia. J Clin Oncol 10:1730–1736

  Google Scholar 

• Sonneveld P, Durie BGM, Lokhorst HM, Marie J-P, Solbu G, Suciu S, Zittoun R, Löwenberg B, Nooter K (1992) Modulation of multidrugresistant multiple myeloma by cyclosporin. Lancet 340:255–259

  Google Scholar 

• Sridhar R, Dwivedi C, Anderson J, Baker PB, Sharma HM, Desai P, Engineer FN (1992) Effects of verapamil on the acute toxicity of doxorubicin in vivo. J Natl Cancer Inst 84:1653–1660

  Google Scholar 

• Thiebaut F, Tsuruo T, Hamada H, Gottesman MM, Pastan I, Willingham MC (1987) Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues. Proc Natl Acad Sci USA 84:7735–7738

  Google Scholar 

• Tsuruo T, Iida H, Tsukagoshi S, Sakurai Y (1981) Overcoming of vincristine resistance in P388 leukemia in vivo and in vitro through enhanced cytotoxicity of vincristine and vinblastine by verapamil. Cancer Res 41:1967–1972

  Google Scholar 

• Van de Vrie W, Gheuens EEO, Durante NMC, De Bruijn EA, Marquet RL, Van Oosterom AT, Eggermont AMM (1993) In vitro and in vivo chemosensitizing effect of cyclosporin A on an intrinsic multidrug-resistant rat colon tumour. J Cancer Res Clin Oncol 119:609–614

  Google Scholar 

• Van Hoesel QGCM, Steerenberg PA, Dormans JAMA, De Jong WH, De Wildt DJ, Vos JG (1986) Time-course study on doxorubicin-induced nephropathy and cardiomyopathy in male and female LOU/M/Wsl rats: lack of evidence for a causal relationship. J Natl Cancer Inst 76:299–307

  Google Scholar 

• Verweij J, Herweijer H, Oosterom R, Van der Burg MEL, Planting ASTh, Seynaeve C, Stoter G, Nooter K (1991) A phase II study of epidoxorubicin in colorectal cancer and the use of cyclosporin A in an attempt to reverse multidrug resistance. Br J Cancer 64:361–364

  Google Scholar 

• Yahanda AM, Adler KM, Fisher GA, Brophy NA, Halsey J, Hardy RI, Gosland MP, Lum BL, Sikic BI (1992) Phase I trial of etoposide with cyclosporine as a modulator of multidrug resistance. J Clin Oncol 10:1624–1634

  Google Scholar 

• Young DM (1975) Pathologic effects of Adriamycin (NSC-123127) in experimental systems. Cancer Chemother Rep 6:159–175

  Google Scholar 

Download references

RetroSearch is an open source project built by @garambo | Open a GitHub Issue

Search and Browse the WWW like it's 1997 | Search results from DuckDuckGo

HTML: 3.2 | Encoding: UTF-8 | Version: 0.7.4